Update on Psychotropic Medications for Cancer-Related Fatigue

Authors:
William Breitbart From Weill Medical College of Cornell University, and the Departments of Psychiatry and Behavioral Sciences and Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York.
From Weill Medical College of Cornell University, and the Departments of Psychiatry and Behavioral Sciences and Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York.
From Weill Medical College of Cornell University, and the Departments of Psychiatry and Behavioral Sciences and Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York.

Search for other papers by William Breitbart in
Current site
Google Scholar
PubMed
Close
 MD
and
Yesne Alici-Evcimen From Weill Medical College of Cornell University, and the Departments of Psychiatry and Behavioral Sciences and Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York.

Search for other papers by Yesne Alici-Evcimen in
Current site
Google Scholar
PubMed
Close
 MD
Full access

Fatigue is a common and highly distressing symptom of cancer associated with reduced quality of life and considerable psychological and functional morbidity. The reported prevalence of cancer-related fatigue ranges from 4% to 91%, depending on the specific cancer population studied and the methods of assessment. Cancer-related fatigue has typically been underreported, underdiagnosed, and undertreated. Fatigue and depression may coexist in cancer patients, and considerable overlap of symptoms occurs. This is partly the reason for the interest in examining the role of psychotropic medications in treating fatigue. Clarifying the relationship between depression and fatigue is necessary to effectively evaluate and treat cancer-related fatigue. Even with International Classification of Diseases criteria, differentiating cancer-related fatigue is difficult. Psychotropic drugs that have been studied for cancer-related fatigue include psychostimulants, wakefulness-promoting agents, and anti-depressants. Methylphenidate has been studied most and seems to be effective and well tolerated despite common side effects. Some preliminary data support using modafinil in cancer-related fatigue with less concern about tolerance or dependence. Antidepressant studies have shown mixed results. Paroxetine seems to show benefit for fatigue primarily when it is a symptom of clinical depression. Bupropion, a norepinephrine/dopamine reuptake inhibitor, may have psychostimulant-like effects, and therefore may be more beneficial for treating fatigue. However, studies are currently limited. Randomized, placebo-controlled trials with specific agents are needed to further assess the efficacy and tolerability of psychotropic medications in the treatment of cancer-related fatigue.

Correspondence: William Breitbart, MD, Memorial Sloan-Kettering Cancer Center, 641 Lexington Avenue, 7th Floor, New York, NY 10022. E-mail: Breitbaw@mskcc.org
  • Collapse
  • Expand
  • 1.

    Curt GA, Breitbart W, Cella D et al.. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353360.

  • 2.

    Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage 2003;26:604614.

  • 3.

    Vogelzang NJ, Breitbart W, Cella D et al.. Patient, caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34:412.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Cella D, Peterman A, Passik S et al.. Progress toward guidelines for the management of fatigue. Oncology 1998;12:369377.

  • 5.

    Mock V, Atkinson A, Barsevick A et al.. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park) 2000;14:151161.

  • 6.

    Lawrence DP, Kupelnick B, Miller K et al.. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004;32:4050.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist 2003;8(suppl 1):59.

  • 8.

    Jacobsen PB, Hann DM, Azzarello LM et al.. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999;18:233242.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Monga U, Kerrigan AJ, Thomby J, Monga TN. Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. Radiat Oncol Investig 1999;7:178185.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Bower JE, Ganz PA, Desmond KA et al.. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18:743753.

  • 11.

    Cella D, Davis K, Breitbart W et al.. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001;19:33853391.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Sadler IJ, Jacobsen PB, Booth-Jones M et al.. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 2002;23:406416.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res 1991;36:291298.

  • 14.

    Schag CC, Heinrich RL, Ganz PA. Karnofsky Performance Status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187193.

  • 15.

    Hann DM, Jacobsen PB, Azzarello LM et al.. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 1998;7:301310.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Mendoza TR, Wang XS, Cleeland CS et al.. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:11861196.

  • 17.

    Piper B, Lindsey A, Dodd M et al.. Development of an instrument to measure the subjective dimension of fatigue. In: Funk SG, Tornquist EM, Champagne MT, et al., eds. Key Aspects of Comfort: Management of Pain, Fatigue and Nausea. New York: Springer; 1989:199208.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995;22:639643.

  • 19.

    Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003;362:640650.

  • 20.

    Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 2002;12:424428.

  • 21.

    Bruera E, Valero V, Driver L et al.. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006;24:20732078.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Reineke-Bracke H, Radbruch L, Elsner F. Treatment of fatigue: modafinil, methylphenidate, and goals of care. J Palliat Med 2006;9:12101214.

  • 23.

    Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92(suppl 6):16841688.

  • 24.

    Monk JP, Phillips G, Waite R et al.. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006;24:18521859.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Hussein MA. Research on thalidomide in solid tumors, hematologic malignancies, and supportive care. Oncology (Williston Park) 2000;14(suppl 12):915.

  • 26.

    Roscoe JA, Morrow GR, Hickok JT et al.. Effect of paroxetine hydrochloride on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005;89:243249.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 2006;11:206216.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Mock V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr 2004;32:112118.

  • 29.

    Mitchell SA, Beck SL, Hood LE et al.. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11:99113.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Sarhill N, Walsh D, Nelson KA et al.. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001;18:187192.

  • 31.

    Sugawara Y, Akechi T, Shima Y et al.. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002;16:261263.

  • 32.

    Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002;29:E8590.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Bruera E, Driver L, Barnes EA et al.. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003;21:44394443.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Hanna A, Sledge G, Mayer ML et al.. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006;14:210215.

  • 35.

    Roth AJ, Nelson CJ, Rosenfeld B et al.. Randomized controlled trial testing methylphenidate as treatment for fatigue in men with prostate cancer [abstract]. Presented at 2006 ASCO Prostate Cancer Symposium; February 24-26, 2006; San Francisco, California. Abstract 275.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Lower E, Fleishman S, Cooper A et al.. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and ``chemobrain'' in adult cancer patients [abstract]. J Clin Oncol 2005;23(suppl 16):729s. Abstract 8000.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Morrow GM, Gillies LJ, Hickok JT et al.. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed [abstract]. J Clin Oncol 2005;23(suppl 16):732s. Abstract 8012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Kaleita TA, Wellisch DK, Graham CA et al.. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors [abstract]. J Clin Oncol 2006;24(suppl 1):58s. Abstract 1503.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Capuron L, Gumnick JF, Musselman DL et al.. Neurobehavioral effects of interferon alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsycho-pharmacology 2002;26:643652.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Morrow GR, Hickok JT, Roscoe JA et al.. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003;21:46354641.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004;49:139144.

  • 42.

    Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology 2006;15:259267.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 2003;64(suppl 11):1418.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001;161:411420.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Holmes VF, Fernandez F, Levy JK. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry 1989;50:58.

  • 46.

    Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000;61:436440.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Bruera E, Brenneis C, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 1989;4:36.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer 2000;8:385397.

  • 49.

    Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006;2:130136.

  • 50.

    Thase ME, Fava M, DeBattista C et al.. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006;11:93102.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    MacAllister WS, Krupp LB. Multiple sclerosis-related fatigue. Phys Med Rehabil Clin N Am 2005;16:483502.

  • 52.

    Bruera E, Roca E, Cedaro L et al.. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985;69:751754.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Bruera E, Ernst S, Hagen N et al.. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998;2:7478.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Cruciani RA, Dvorkin E, Homel P et al.. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage. 2006;32:551559.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Bruera E, Strasser F, Shen L et al.. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003;26:10491054.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Pucci E, Branas P, D'Amico R et al.. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007;(1):CD002818.

  • 57.

    Burks TF. New agents for the treatment of cancer-related fatigue. Cancer 2001;92(suppl 6):17141718.

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1104 200 45
PDF Downloads 517 135 12
EPUB Downloads 0 0 0